The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Ibrutinib-rituximab for CLL: efficacious, but challenging toxicity profile
Ibrutinib has demonstrated marked efficacy in chronic lymphocytic leukemia (CLL). Jacqueline Barrientos, MD, Northwell Health, New York, NY, outlines the toxicity profile of ibrutinib and discusses the extended follow-up results of the E1912 trial (NCT02048813). Among the 95 patients who discontinued ibrutinub, 51% was due to adverse events and toxicities. Dr Barrientos reveals that adverse events should be identified early to avoid greater complications. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
